IL280632A - Methods and compositions for inhibiting the egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors - Google Patents

Methods and compositions for inhibiting the egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors

Info

Publication number
IL280632A
IL280632A IL280632A IL28063221A IL280632A IL 280632 A IL280632 A IL 280632A IL 280632 A IL280632 A IL 280632A IL 28063221 A IL28063221 A IL 28063221A IL 280632 A IL280632 A IL 280632A
Authority
IL
Israel
Prior art keywords
באנגלית
cobination
egf
english
inhibition
Prior art date
Application number
IL280632A
Other languages
English (en)
Hebrew (he)
Inventor
Erik D'hondt
Miguel Angel Molina-Vila
Original Assignee
In3Bio Ltd
Dhondt Erik
Molina Vila Miguel Angel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In3Bio Ltd, Dhondt Erik, Molina Vila Miguel Angel filed Critical In3Bio Ltd
Publication of IL280632A publication Critical patent/IL280632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL280632A 2018-08-07 2021-02-02 Methods and compositions for inhibiting the egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors IL280632A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862715351P 2018-08-07 2018-08-07
US201862727056P 2018-09-05 2018-09-05
US201862748772P 2018-10-22 2018-10-22
US201862760529P 2018-11-13 2018-11-13
US201962822290P 2019-03-22 2019-03-22
PCT/IB2019/000905 WO2020030977A2 (en) 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors

Publications (1)

Publication Number Publication Date
IL280632A true IL280632A (en) 2021-03-25

Family

ID=68425157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280632A IL280632A (en) 2018-08-07 2021-02-02 Methods and compositions for inhibiting the egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors

Country Status (11)

Country Link
US (1) US12257245B2 (enExample)
EP (1) EP3833384A2 (enExample)
JP (1) JP2021534094A (enExample)
KR (1) KR20210041571A (enExample)
CN (1) CN112996534B (enExample)
AU (1) AU2019319109A1 (enExample)
BR (1) BR112021002145A2 (enExample)
CA (1) CA3108236A1 (enExample)
IL (1) IL280632A (enExample)
MX (1) MX2021001398A (enExample)
WO (1) WO2020030977A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
WO2022256360A1 (en) * 2021-06-02 2022-12-08 Neuvogen, Inc. Tumor cell vaccines
WO2023059801A1 (en) * 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
CA3236522A1 (en) * 2021-10-28 2023-05-04 In3Bio Ltd. Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
WO2023138576A1 (zh) * 2022-01-18 2023-07-27 齐鲁制药有限公司 螺环芳基磷氧化物与抗egfr抗体的药物组合
WO2024017352A1 (zh) * 2022-07-22 2024-01-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024249331A1 (en) * 2023-05-26 2024-12-05 The Board Of Regents Of The University Of Texas System Combined rtk and alk inhibition in rtk driven cancers
KR20250120789A (ko) 2024-02-02 2025-08-11 제이투에이치바이오텍 (주) E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
RS54689B1 (sr) 2012-03-06 2016-08-31 Cephalon, Inc. Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor
EP2890815B1 (en) * 2012-08-31 2019-03-20 The Regents of the University of Colorado Methods for diagnosis and treatment of cancer
US20160017431A1 (en) * 2014-03-28 2016-01-21 Driver Group Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy
SG11201608303QA (en) * 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
MX2017015937A (es) * 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
JP2018521019A (ja) * 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
JP7751357B2 (ja) 2017-07-18 2025-10-08 イン３バイオ・リミテッド 合成タンパク質およびその治療学的用途
RU2654695C1 (ru) 2017-07-28 2018-05-22 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака

Also Published As

Publication number Publication date
WO2020030977A3 (en) 2020-06-18
JP2021534094A (ja) 2021-12-09
EP3833384A2 (en) 2021-06-16
CN112996534A (zh) 2021-06-18
MX2021001398A (es) 2021-08-16
CN112996534B (zh) 2025-11-18
US12257245B2 (en) 2025-03-25
KR20210041571A (ko) 2021-04-15
BR112021002145A2 (pt) 2021-12-14
WO2020030977A2 (en) 2020-02-13
US20200046690A1 (en) 2020-02-13
AU2019319109A1 (en) 2021-02-25
CA3108236A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
IL280632A (en) Methods and compositions for inhibiting the egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors
MY204609A (en) Imidazole-containing inhibitors of alk2 kinase
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
EP3852769A4 (en) ARNI AGENTS FOR INHIBITING EXPRESSION OF 17BETA-HSD TYPE 13- (HSD17B13), THEIR COMPOSITIONS AND METHODS OF USE
IL281805A (en) Quinazoline derivatives as tyrosine kinase inhibitors, preparations, methods for their preparation and use
EP3250192A4 (en) Compositions and methods of using tyrosine kinase inhibitors
ZA201807256B (en) Inhibitors of activin receptor-like kinase
PH12017501155B1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
IL281939A (en) VAP-1 inhibitors
IL275539A (en) Compounds and methods for inhibiting expression of ALDH2
SG11202103142TA (en) Heterocyclic kinase inhibitors and uses thereof
IL277600A (en) AXLkinase inhibitors and their use
IL281815A (en) VAP-1 inhibitors
IL292860B1 (en) EGFR allosteric inhibitors and methods of using them
IL255582A (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
EP3999064A4 (en) Inhibitors of tyrosine kinase
HK40055900A (en) Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors
SG11202008851UA (en) Morpholine derivates as inhibitors of vps34
GB201709417D0 (en) Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
ZA202103858B (en) Tyrosine kinase inhibitors, compositions and methods there of
EP3774818A4 (en) TYROSINE KINASE INHIBITORS FMS TYPE
GB201807845D0 (en) Kinase Inhibitors
HK40029221A (en) Kinase inhibitors and methods for making and using
HK40037550A (en) Compositions and methods for inhibiting aldh2 expression
IL291450A (en) : methods and compositions for inhibiting src kinase and treating and preventing associated disorders